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BACKGROUND AND PURPOSE
Transient receptor potential (TRP) channels are a superfamily of non-selective cation permeable channels involved in peripheral
sensory signalling. Animal studies have shown that several TRPs are important players in pain modulation. Among them, the TRP
melastatin 8 (TRPM8) has elicited more interest for its controversial role in nociception. This channel, expressed by a subpopu-
lation of sensory neurons in dorsal root ganglia (DRG) and trigeminal ganglia (TG), is activated by cold temperatures and cooling
agents. In experimental neuropathic pain models, an up-regulation of this receptor in DRG and TG has been observed, suggesting
a key role for TRPM8 in the development andmaintenance of pain. Consistent with this hypothesis, TRPM8 knockout mice are less
responsive to pain stimuli.
EXPERIMENTAL APPROACH
In this study, the therapeutic potential and efﬁcacy of two novel TRPM8 antagonists, DFL23693 and DFL23448, were tested.
KEY RESULTS
Two potent and selective TRPM8 antagonists with distinct pharmacokinetic proﬁles, DFL23693 and DFL23448, have been fully
characterized in vitro. In vivo studies in well-established models, namely, the wet-dog shaking test and changes in body temper-
ature, conﬁrmed their ability to block the TRPM8 channel. Finally, TRPM8 blockage resulted in a signiﬁcant antinociceptive effect
in formalin-induced orofacial pain and in chronic constriction injury-induced neuropathic pain, conﬁrming an important role for
this channel in pain perception.
CONCLUSION AND IMPLICATIONS
Our ﬁndings, in agreement with previous literature, encourage further studies for a better comprehension of the therapeutic
potential of TRPM8 blockers as novel agents for pain management.
Abbreviations
CCI, chronic constriction injury; DPA, Dynamic Plantar Aesthesiometer; DRG, dorsal root ganglia; hERG, human ether-a-
go-go related gene; Tb, body temperature; TRPM8, transient receptor potential melastatin 8; WDS, wet-dog shake
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Introduction
Transient receptor potential melastatin 8 (TRPM8) belongs
to the TRP superfamily of cation channels. It is acti-
vated by moderate cold and exogenous ‘cooling-mimetic’
compounds, such as menthol and icilin (McKemy et al.,
2002; Peier et al., 2002), and is considered the principal sensor
for innocuous cold (Takashima et al., 2007; Dhaka et al.,
2008). In coherence with its function as a thermal sensory
sentinel, several studies have shown that TRPM8 is strongly
expressed in a subpopulation of primary sensory neurons
within the dorsal root (DRG) and trigeminal ganglia
(McKemy et al., 2002). Speciﬁcally, it is widely expressed on
terminals of thermosensitive neurons that innervate periph-
eral tissues including the skin, tongue, teeth and cornea (Abe
et al., 2005; Parra et al., 2010). Several studies in animals and
humans have clearly demonstrated the role of TRPM8 in
pain perception (Marwaha et al., 2016); nevertheless, its pre-
cise role in pain modulation remains a matter of debate
(Namer et al., 2005; Proudfoot et al., 2006). Application of
relatively low doses of menthol (TRPM8 agonist) is associ-
ated with a cooling sensation and even pain relief, while at
higher doses, the same drug causes burning, irritation and
pain (Wasner et al., 2004; Hatem et al., 2006). Similarly, both
TRPM8 activators and blockers have been demonstrated to
attenuate pain sensation in neuropathic pain models (Parks
et al., 2011; Sałat and Filipek, 2015). The conﬂicting results
of these studies anticipate a complex and multifaceted role
of TRPM8 in the pathophysiology of nociception, but the ev-
idence that TRPM8/mice are deﬁcient of innocuous cold
and partially of noxious cold sensitivity strongly support
the not-redundant function of this channel (Colburn et al.,
2007). Interestingly, preclinical studies have shown that
levels of TRPM8 protein and RNA are both increased in
sciatic nerve ligated (Frederick et al., 2007; Xing et al., 2007)
and spinal nerve ligated rats (Koh et al., 2016). Studies with
TRPM8-deﬁcient mice have also demonstrated the involve-
ment of TRPM8 activation in chemotherapy-induced
hypersensitivity to innocuous and noxious cold stimuli
(Descoeur et al., 2011).
The role of TRPM8 in cold hyperalgesia, a frequent symp-
tom of neuropathic pain, has been also conﬁrmed in clinical
studies in humans. Topical application of the TRPM8 agonist
menthol is a well-characterized human model of cold pain,
and several studies have demonstrated that menthol induces
spontaneous burning pain and cold hyperalgesia by activa-
tion and sensitization of C-nociceptors (Wasner et al., 2004;
Campero et al., 2009). Thus, whereas converging evidence
suggests that TRPM8 inhibition could be a valuable pharma-
cological strategy for the control of inﬂammatory and neuro-
pathic pain, the poor selectivity of the agonists/antagonists
commonly used in animal models has so far impaired the full
assessment of TRPM8 as a potential pharmacological target.
To better understand the relevance of TRPM8 modulation,
we ran amedicinal chemistry programme that led to the iden-
tiﬁcation of two potent and selective TRPM8 antagonists,
with a pharmacological proﬁle suitable for the treatment of
pain disorders. The aim of this study was to test the efﬁcacy
of these TRMP8 blockers in acute and chronic animal pain
models and to evaluate their effects on body temperature
and on icilin-induced wet-dog shaking.
Methods
In vitro TRPM8 assay
The in vitro human TRPM8 cell-based assay was performed by
Axxam, Italy.
The TRPM8 antagonist activity of the compounds was de-
termined by measuring changes in intracellular calcium
levels triggered by the agonists cooling agent 10 and icilin
by using a Ca2+ sensitive ﬂuorescent dye. The experiments
were performed using HEK-293 cells stably expressing the hu-
man TRPM8. Cells were seeded 10.000 cells per well and
grown at 37°C (% CO2) in complete medium in 384-well
plates coated with poly-D-lysine (Matrix black/clear bottom;
Thermo Scientiﬁc, Waltham, MA). Twenty-four hours after
seeding of the cells, cell culture medium was removed; cells
were washed with Tyrode’s assay buffer and then loaded with
the ﬂuorescent Ca2+ indicator Fluo-4 NW dye (Molecular
Probes, Life Technologies, Paisley, UK) supplemented with
water-soluble probenecid (Molecular Probes). Dye-loaded
cell plates were incubated for 1 h at room temperature. The
compounds or vehicle were added, and the kinetic response
was monitored by a ﬂuorimetric imaging plate (FLIPRTETRA;
Molecular Devices, Sunnyvale, CA) over a period of 5 min.
Then an injection of the reference agonist, cooling agent
10, at its EC80 concentration was performed. The signal of
the ﬂuorescence emitted was recorded for an additional
3 min. The bioactivity exerted by the compounds or vehicle
was expressed as % inhibition, and IC50 values were then cal-
culated. The percentage scale is deﬁned by a 100% inhibition
in which the relative ﬂuorescence units (RFUs) of the test
were identical to the MIN controls in second injection
(capsazepine at IC100, 50 μM) and 0% of inhibition in
which the RFUs of the test were identical to theMAX controls
in second injection (cooling agent 10 and icilin at EC80,
20–30 μM).
The % activity was calculated according to the following
formula:
%activity ¼ 100 x < MAX >
< MIN >  < MAX >
 
:
<MAX>: median of max signal controls.
<MIN>: median of min signal controls.
x: measured value of a well.
Compounds were tested at eight concentrations in qua-
druplicate to determinate the IC50 towards both cooling
agent 10 and icilin activation. Evaluation of compound activ-
ity proﬁle was performed with Genedata Screener 12.0.5.
In vitro cold stimulation assay
The in vitro human TRPM8 cell-based assay with a low temper-
ature stimulation protocol was performed by Axxam, Italy.
The temperature-activation cell-based assay described by
Aneiros and Dabrowski (2009) was modiﬁed and used to as-
sess the ability of DFL23448 and DFL23693 to inhibit cold-
induced TRPM8 stimulation. HEK-293 cells stably expressing
human TRPM8 were seeded (1.5–1.8 × 106 cells) in a T75 ﬂask
in complete medium. Three to four days after seeding (ap-
proximately 80% conﬂuent cells), the medium was removed,
and cells were loaded with Screen QuestTM Fluo-8 NW dye
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solution (ABD Bioquest, Sunnyvale, CA, USA). Dye-loaded
cell ﬂasks were incubated for 45 min at room temperature in
the dark, and the Fluo-8 NW solution was then removed,
and cells were seeded in 96-well assay plates (MicroAmpTM
Optical 96-Well Reaction Plates; Applied Biosystems, Life
technologies) at 100.000 cells per well (20 μL per well). The
compounds were added and incubated at room temperature
for 5 min. The signal was recorded for 2 min at 25°C; then
the temperature was lowered to sub-physiological levels,
and the signal recorded for 3 min by the ABI Prism®
7900HT Sequence Detection System (Life Technologies).
The ﬂuorescence difference (ΔF = ﬂuorescence525nm at 14°C
– ﬂuorescence525nm at 25°C) was assessed. The analysis was
performed computing ΔF/F0, where F0 was the ﬂuorescent
signal at the starting temperature (25°C).
ΔF/F0 was normalized versus Neutral Controls (max sig-
nals) and Inhibitor Controls (min signals) in order to obtain
% activity according to the following formula:
%activity ¼ 100 x < MAX >
< MIN >  < MAX >
 
;
where
<MAX>: median of max signal controls.
<MIN>: median of min signal controls.
x: measured value of a well.
Compounds were tested at eight concentrations in qua-
druplicate to determinate the IC50.
IC50 curves were generated by ﬁtting the ﬂuorescence
data with a sigmoidal curve equation using GraphPad
PRISM® software (version 5, GraphPad Software Inc., La
Jolla, CA, USA).
In vitro ion channels selectivity assay
The proﬁling of the compounds on human TRPA1, TRPV1,
TRPV4 and Nav1.7 ion channels was performed by Axxam,
Italy.
TRPA1-, TRPV1-, TRPV4- and Nav1.7-expressing HEK-293
cells were analysed in order to study the response to the com-
pounds using a Ca2+ mobilization-dependent ﬂuorescence
signal in 384 MTP format. Cells were seeded 10 000 cells per
well in 384 MTP (Matrix black/clear bottom plates) in com-
plete medium (25 μL per well). Twenty-four hours after
seeding the cells, the medium was removed, and cells were
loaded with 20 μL per well of the Fluo-8 NW dye solution.
The dye-loaded cell plates were incubated for 1 h at room
temperature. Test compounds at 3X concentration in 1.5%
DMSO Tyrode’s buffer were added to the wells of an assay
plate, in 10 μL volume (for a ﬁnal DMSO concentration of
0.5%) and read by the FLIPRTETRA plate. The kinetic response
was monitored by the instrument over a period of 3 min
(200 s). A second injection of (10 μL per well) of reference ag-
onists (capsaicin, GSK1016790A, isothiocyanate and
veratridine for TRPA1, TRPV1, TRPV4 and Nav1.7 respec-
tively) at 4 x concentration in assay buffer (EC80) was added
by the FLIPRTETRA. The signal of the emitted ﬂuorescence
was recorded for an additional 3 min.
The inhibitory effect (% activity) of the compounds was
calculated according to the following formula:
%activity ¼ 100 x < MAX >
< MIN >  < MAX >
 
;
where
<MAX>: median of max signal controls.
<MIN>: median of min signal controls.
x: measured value of a well.
Compounds were tested at eight concentrations in qua-
druplicate to determinate the IC50 towards the panel of ion
channels. The compound curve ﬁtting proﬁle for each
dose–response was performed with the Condoseo module of
Genedata Screener 13.0.5.
Physicochemical characterization
The main physicochemical properties of the compounds
(pKa and solubility) were determined by using the SiriusT3
apparatus (Sirius Analytical Instruments Ltd., East Sussex,
UK) equipped with an Ag/AgCl double junction reference
pH electrode, a Sirius D-PAS spectrometer and a turbidity
sensing device. The titration experiments were conducted in
0.15 M KCl solution under an argon atmosphere at a temper-
ature of 25 ± 1°C.
All tests were performed using standardized 0.5 M KOH
and 0.5 M HCl as titration reagents.
DFL23448 and DFL23693 were analysed in triplicate
(n = 3) solutions (Gibco PBS 1X, pH 7.4) at a concentra-
tion of 10 μM to test their stability towards the hydrolysis
reaction. Incubations were performed at 37°C for 5 days.
Samples were then transferred in vials for LC–MS/MS
analysis.
Radioligand binding assay for selectivity versus
GPCRs
Evaluation of the afﬁnity of DFL23448 and DFL23693 for
human adrenoceptors (α1A, α2A, β1 and β2), histamine
receptors (H1 and H2), ACh muscarinic receptors (M2
and M3), the neurokinin NK1 receptor, opioid receptors
(δ, κ and μ), the opioid receptor NOP (also known as
ORL1), the 5-HT1A receptor, cannabinoid receptors
(CB1 and CB2), dopamine receptors (D2 and D3) and
bradykinin receptors (B1 and B2) was performed by
Euroﬁns Cerep SA (France) by radioligand binding assays.
Cell membrane homogenates (48 μg protein) were incu-
bated for 60 min at 22°C with the respective reference
compound in the absence or presence of the test com-
pound in a buffer containing 50 mM Tris–HCl (pH 7.4),
2 mM MgCl2 and 1 mM EDTA. After incubation, the sam-
ples were ﬁltered rapidly under vacuum through glass ﬁbre
ﬁlters (GF/B, Packard Instruments, Meriden, CT, USA)
presoaked with 0.3% polyethylenimine and rinsed several
times with ice-cold 50 mM Tris–HCl using a 96-sample cell
harvester (Uniﬁlter, Packard Instruments). The ﬁlters were
dried, then counted for radioactivity in a scintillation coun-
ter (Topcount, Packard Instruments) using a scintillation
cocktail (Microscint 0, Packard Instruments). The results
are expressed as % inhibition of the control radioligand spe-
ciﬁc binding. The compounds were tested at a single con-
centration of 10 μM in triplicate.
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hERG inhibition
The human ether-a-go-go related gene (hERG) inhibition
assay was performed by Euroﬁns Panlabs Inc, USA.
Compounds were tested to assess the potential interaction
on hERG (Kv11.1) channel stably transfected in CHO-K1
cell line. Single cell ionic currents were measured in the
automated patch clamp conﬁguration at room temperature
by using QPatch 16 instrument. The compounds were tested
at ﬁve concentrations in triplicate to obtain the IC50 values.
Cytochrome P450 inhibition
The cytochrome P450 inhibition assay was performed by
Euroﬁns Panlabs Inc, USA. The compounds were tested to
evaluate the potential direct inhibitory effect on the major
human cytochrome P450 enzyme isoforms (CYP3A4,
CYP1A2, CYP2C9, CYP2C19 and CYP2D6) after incuba-
tion with pooled human liver microsomes using testoster-
one/midazolam, phenacetin, diclofenac, omeprazole
and dextromethorphan as probe model substrates for
CYP3A4, CYP1A2, CYP2C9, CYP2C19 and CYP2D6
respectively.
Test compounds were incubated for 10 min at 37°C with
human liver microsomes (0.1 mg·mL1) and NADPH
(1 mM) in the presence of a cytochrome P450 isoform-
speciﬁc probe substrate. The metabolite concentrations were
then monitored by LC–MS/MS spectrometry. A decrease in
the formation of the metabolite compared with the vehicle
control was used to calculate the IC50 value. The effect of
DFL23448 and DFL23693 was tested at ﬁve concentrations
in triplicate.
Plasma protein binding
The evaluation of protein binding of DFL23448 and
DFL23693 in rat plasma was performed by Aphad, Italy.
Stock solutions of the compounds and of the reference
standards (diclofenac and antipyrine) were prepared in
DMSO at a ﬁnal concentration of 2 mM. Then 1.5 μL of com-
pounds were spiked in 298.5 μL of plasma to obtain a ﬁnal
concentration of 10 μM. Plasma (200 μL) in triplicate for each
compound was dialysed in the rapid equilibrium dialysis
(RED) inserts (Thermo Scientiﬁc) against 350 μL of PBS in
the RED plate for 4 h at 37°C, under agitation. At the end of
the incubation, 50 μL of plasma was added to 50 μL of blank
PBS buffer and 300 μL of acetonitrile (with 2.5 ng·mL1 of
verapamil as internal standard).
Similarly, 50 μL of incubated PBS was added to 50 μL of
blank plasma and 300 μL of acetonitrile with verapamil. Sam-
ples were centrifuged at 12 000× g for 5min, and supernatants
were transferred in vials for LC–MS/MS analysis.
Drug treatment
DFL23448 and DFL23693 were dissolved in 10% v/v of
Solutol HS 15: N-methyl pyrrolidone in the ratio 2:1 w.v-1
and mixed at T = 40°C until complete dissolution. Then
90% v.v-1 of PBS was added to these solutions and mixed
(50°C) for 2–3 min; they were adjusted to pH 7.4–7.5 with
NaOH (0.1 N) and mixed (40°C) for 2–3 min until complete
dissolution. DFL23448 and DFL23693 were prepared daily
before use.
For the pharmacokinetic studies, only, DFL23448 was dis-
solved in 50% PEG400 and 50% PBS, pH 7.4.
Pharmacokinetics studies in the rat
Pharmacokinetic studies were carried out by Aphad, Italy.
PK parameters for DFL23448 were determined following
i.v. and p.o. administration at 3 and 10 mg·kg1 respectively
(ﬁve male Sprague–Dawley rats, 7–8 weeks of age, were used
for each dose). For DFL23693, ﬁve male Sprague–Dawley rats
were dosed at 5 mg·kg1 (i.v.) and 10 mg·kg1 (p.o.). After ad-
ministration of the compounds, 0.15–0.20 mL of blood were
collected via jugular vein catheters with the use of zero-dead
volume disposable syringes (1 mL insulin syringes with at-
tached 25G 5/8 inch needles). Blood samples were taken at
0.12 (i.v. only), 0.25, 0.5, 1, 2, 4, 8, 10 and 24 h post-dose. Af-
ter each blood withdrawal, the catheters were washed with
0.15–0.2 mL of sterile physiological saline and ﬁlled with
0.03 mL of heparin saline solution (0.25 U·mL1). The
heparin-treated blood was immediately centrifuged (6000× g
for 5 min at approximately 4°C), and the resulting plasma
collected and transferred to uniquely labelled eppendorfs
and frozen at 20°C until the analysis.
At the end of the study, animals were killed by exsangui-
nation under deep isoﬂurane anaesthesia.
Calibration curves and QC samples were prepared in rat
blank plasma adding 2 μL of each stock solution to 18 μL of
plasma. Ten microlitres of spiked plasma was then added to
200 μL of cold acetonitrile with the internal standard at the
ﬁnal concentration of 100 ng·mL1. Samples were kept
under agitation for 15 min and centrifuged for 5 min at
9000× g at 5°C.
DFL23448 and DFL23693 concentrations were quantiﬁed
by ULPC–MS/MS using a chromatographic method with a
lower limit of quantitation of 1 ng·mL1.
PK parameters were calculated using non-com-
partmental analysis in Phoenix WinNonlin, Version 6.3
(Certara, L.P. – USA): AUC (0-inf) was calculated using a
non-compartmental pharmacokinetic analysis with the
linear-logarithmic trapezoidal rule; half-life (t1/2) was calcu-
lated by linear regression on semi-log plot of plasma
concentration versus time (at least 3 time points during
the terminal elimination phase with R2 > 0.85).
Animals
The behavioural experiments were performed on male
Sprague–Dawley rats (7–9 weeks of age; Charles River, Italy)
housed in the animal care facility of the Department of Phar-
macy of the University of Naples, Italy. Animals were housed
in groups of ﬁve, in a room with controlled temperature
(22 ± 1°C), humidity (60 ± 10%) and light (12 h per day); food
and water were available ad libitum throughout the study. All
animals were weighed on the day of each treatment. All be-
havioural tests were performed between 09:00 and 17:00 h,
and the animals were used only once. Animal care and ma-
nipulations were conducted in conformity with Interna-
tional and National law and policies (EU Directive 2010/63/
EU for animal experiments, ARRIVE guidelines and the Basel
declaration including the 3R concept). The procedure re-
ported here was approved by the Institutional Committee
on the Ethics of Animal Experiments (CVS) of the University
of Naples Federico II and by Ministero della Salute under
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protocol no. 2014-00884607. Animal studies are reported in
compliance with the ARRIVE guidelines (Kilkenny et al.,
2010; McGrath and Lilley, 2015).
For the pharmacokinetic studies, not-fasted male
Sprague–Dawley male rats were used and purchased from
Harlan Italy Srl (body weights 250 g at the time of the treat-
ment). The animals were housed, in a group of ﬁve, in cages
suitable for the species, also during dosing and feeding
periods. The animals were acclimatized to local housing
conditions for 5 days and housed in a single, exclusive room,
air-conditioned to provide a minimum of 15 air changes per
hour. The environmental controls were set to maintain tem-
perature at 22°C and relative humidity within the range 50
to 60% with an approximate 12 h light and 12 h dark cycle
that is controlled automatically. Food and water were avail-
able ad libitum throughout the study. All animals were
weighed on the day of each treatment. Clinical signs were
monitored at regular intervals throughout the study in order
to assess any reaction to treatment. Each animal was uniquely
identiﬁed with a coloured spray on the back before the exper-
iment. The experiment was carried on in agreement with the
Italian Law D. L.vo 4 Marzo 2014, no. 26.
Experimental groups and procedures
For the behavioural experiments, rats were randomized and
divided into equal-sized groups (n = 10 per group) not
predetermined by a statistical method. Animals were treated
with vehicle, DFL23693 (10 mg·kg1, p.o.) and DFL23448
(10 mg·kg1, i.v.). The volume of liquid administered was
0.5 mL for p.o. administration and 0.3 mL for i.v. Details of
the anaesthesia are provided below. At the end of the proce-
dures, the animals were killed by cervical dislocation.
Induction of orofacial and neuropathic pain
Orofacial pain hypersensitivity was induced by formalin ac-
cording to the method described by Raboisson and Dallel
(2004) with some modiﬁcations. Brieﬂy, 2.5% formalin
(0.1 mL) was injected into the upper lip, just lateral to the
nose using a 27G sterile needle mounted on a 1 mL syringe;
the needle was inserted into the lip close to the border be-
tween hairy and glabrous skin and advanced up to the hilt to-
wards the vibrissal pad. Thus, the formalin solution spread
out within the upper lip and the rostral half of the vibrissal
pad inducing a stereotypical response characterized by two
distinct phases: an initial neurogenic phase (0–3 min) and a
second inﬂammatory phase (10–30 min). Differently from
Raboisson and Dallel’s method, we evaluated pain hypersen-
sitivity by mechanical and cold stimuli developed 24 h after
formalin injection using the Orofacial Stimulation Test
(Ugo Basile, Italy).
Neuropathic pain behaviour was induced by ligation of
the sciatic nerve according to the method described by Ben-
nett and Xie (1988). Rats were anaesthetized (100 mg·kg1
ketamine and 10 mg·kg-1 xylazine i.p.), and the left sciatic
nerve was exposed at the level of the thigh by blunt dissec-
tion through the biceps femoris. We assessed the depth of an-
esthesia through absent of reﬂex in response to noxious
stimuli such as pinch of paw. Proximal to the sciatic’s trifurca-
tion, about 12 mm of nerve was freed of adhering tissue, and
four ligatures were loosely tied around it with about 1 mm
spacing so that the epineural circulation was preserved. The
length of nerve thus affected was 6–8 mm long. The animals
were allowed to recover and used the day after the surgery.
Sham rats underwent the same surgical procedure to expose
but not ligate the left sciatic nerve.
Orofacial stimulation test
The orofacial stimulation test systemmeasures hypersensitiv-
ity of the trigeminal area. Animals initially underwent 5 days
of training utilizing the orofacial stimulation test after a 12 h
period of food deprivation (fasting period). Rats were placed
in a standard rat cage with a plastic divider to create two
rooms. In the anterior room of the cage, there was an Ugo
Basile apparatus with a drinking window for the rat’s head
to enter and acquire a reward (milk and chocolate) located
on the opposing aspect of the drinking window. During the
training period, each rat was individually placed in the poste-
rior room for 10min to familiarize it to its environment, then
the drinking window was opened, and the test rat was subse-
quently monitored for 10 min to allow it to drink the milk
and chocolate (Zuo et al., 2013). At the day of behavioural as-
sessment, mechanical or thermal stimulation was induced by
the insertion of an appropriate module in the drinking win-
dow (not present during the training period). During this
time, rats received approximately 3–5 stimulations prior to
formalin (basal) and 15–20 stimulations 24 h after formalin
injection, for both mechanical and thermal stimulator. Simi-
lar to the adaptation training, all thermal or mechanical mod-
ule experiments were preceded by a 12 h fasting period,
10 min for the rats to be familiarized with testing environ-
ment and a subsequent 10 min for behavioural assessment.
Mechanical stimulator
Experiments were performed utilizing the mechanical model
that consisted of a cassette with 10 tungsten wires placed
3mm apart from each other and 8mm from the opening hole
to the cassette held to produce a bending force from the drink-
ing window of the apparatus. The animal’s face contacted the
tungsten wires of the mechanical module as the rat projected
its head through the hole in the apparatus in order to drink
milk and chocolate located on the exterior aspect of the drink-
ing window. In each experiment, a blind observer activated a
stopwatch every time the test rat drank milk and chocolate
(also deﬁned as ‘contact time’); when the test rat moved away
from the drinking window, the stopwatch was stopped. Data
were generated using the total contact time(s) to mechanical
stimulus reached in a total testing time of 600 s. Basal data
were obtained from the total contact time (reached in a total
testing time of 600 s) 24 h before formalin injection.
Thermal stimulator
In the thermal model, there was a surrounding metal tubing
at the opening; the temperature of the circulating solution
(water) was controlled by a thermal circulating bath unit
(Ugo Basile, Italy). The distance between the metal tube and
the nipple of the milk/chocolate bottle was 14 mm. For ther-
mal stimulation, the thermal module was set at 5°C; the ani-
mal’s orofacial region was shaved 3 days before formalin
injection and subjected to cold stimuli when the rat
contacted themetal tube as it poked its head through the hole
to obtain the milk/chocolate. In each experiment, a blind ob-
server activated a stopwatch every time that the test rat drank
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milk and chocolate (also deﬁned as ‘contact time’); when the
test rat moved away from the drinking window, the stop-
watch was stopped. Data were generated from the total con-
tact time(s) to thermal stimulus reached in a total testing
time of 600 s. Basal data were obtained from the total contact
time (reached in a total testing time of 600 s) 24 h before for-
malin injection.
Mechanical allodynia
To assess the changes in sensation or in the development of
mechanical allodynia, sensitivity to tactile stimulation was
measured using the Dynamic Plantar Aesthesiometer (DPA,
Ugo Basile, Italy). Individual animals were placed in plexiglas
boxes (30 × 30 × 25 cm) with a mesh metal ﬂoor covered by a
plastic dome that enabled the animal to walk freely, but not
to jump, for approximately 30 min thus allowing behav-
ioural acclimatization to the environment. When both paws
were resting on the ﬂoor, the experimenter started the test.
The mechanical stimulus was then delivered in the mid-
plantar skin of the hind paw. The cut-off was ﬁxed at 50 g. Ip-
silateral and contralateral paws were tested twice per session,
before ligation (day 0) and then 7 and 14 days after surgery at
1, 3 and 5 h post dose. The means of the paws withdrawal
(express in g) were calculated from an average of two separate
measures.
Cold allodynia
Cold sensitivity was measured as the number of foot with-
drawal responses after application of acetone to the dorsal
surface of the paw (Choi et al., 1994). Individual animals were
placed in Plexiglas boxes (30 × 30 × 25 cm). A drop of acetone
(25 μL) was applied over the dorsal surface of the paws with a
syringe connected to a thin polyethylene tube while the rats
were standing on a metal mesh. A brisk foot withdrawal re-
sponse, after the spread of acetone, was considered as a sign
of cold allodynia. No familiarization period was required, be-
cause it was not necessary for the animal’s paw to be on the
ﬂoor. Cold responses were measured on ipsilateral (ligated)
and contralateral paws 7 and 14 days after surgery at 1, 3
and 5 h post dose. The procedure was repeated 3 times at
5 min intervals. In results are reported as the mean of the
paw withdrawal (expressed as a number) determined from
an average of three separate measures.
Experimental design
The effect of DFL23693 was evaluated 3 h following p.o. ad-
ministration, while the effect of DFL23448 was evaluated
1 h following i.v. administration, in agreement with their
pharmacokinetic characteristics. Antinociceptive activity by
mechanical and thermal stimuli was measured 24 h after for-
malin treatment; two separate experiments were done.
In the neuropathic pain experiment, the antiallodynic ef-
fect of the compounds was evaluated on days 7 and 14 after
nerve ligation.
Body temperature
Rats were placed into an environmental room maintained at
a constant temperature of 21 ± 0.3°C and relative humidity
of 55 ± 2%. The animals were allowed to acclimatize for
24 h before taking the ﬁrst temperature reading. Body tem-
perature (Tb) was recorded using a rectal probe for rats (Model
RAT2, Ugo Basile, Italy), which was inserted approximately
5 cm into the colon. A digital thermometer (Model BAT-10,
Ugo Basile, Italy) was used. Vehicle (p.o. or i.v.), DFL23693
(10 mg·kg1 p.o.) and DFL23488 (10 mg·kg1 i.v.) were ad-
ministered for four consecutive days; each day; Tb was mea-
sured before treatment (baseline) and at 1, 3, 5 and 7 h
following DFL23693 administration and at 0.5, 1, 2 and 3 h
following DFL23448 administration, according to their dif-
ferent pharmacokinetic proﬁles.
Icilin-induced “wet-dog” shaking in rats
Icilin, a TRPM8 agonist, was used to induce shaking in rats
(Wei, 1983). Animals were ﬁrst habituated to the testing
room for 30 min; after that, they were randomized into treat-
ment groups and treated with vehicle (p.o. or i.v.) or
DFL23693 (10 mg·kg1 p.o.) or with DFL23488 (10 mg·kg1
i.v.). Icilin was administered i.p. at 1 mg·kg1 dissolved in
1% Tween80/H2O. The number of intermittent but rhythmic
‘wet dog-like’ shakes (WDS) of neck, head and trunk in each
animal was counted for a period of 30min following icilin ad-
ministration. DFL23693 and DFL 23448 were, respectively,
administered 3 and 1 h before icilin injection.
Blinding and randomization
For most in vitro protocols, blinding was not feasible as exper-
iments were conducted by an individual experimenter,
whereas in in vivo experiments, drug treatments were con-
ducted in a blinded fashion. In neuropathic pain experi-
ments, we excluded the sham group from blinding
conditions since all rats subjected to chronic constriction in-
jury (CCI) had a unique posture as they tended to retract the
ipsilateral paw and to hold it up from the ﬂoor, in a guarding
posture, whereas sham rats did not show this behaviour. In all
in vivo tests, randomization of animals and treatments were
performed by different experimenters. Animals were allo-
cated to experimental groups based on their baseline re-
sponses to behavioural tests. In order to reduce the effect of
extraneous variables on behavioural assessment, concurrent
vehicle-treated groups were present throughout all experi-
ments. All treatments were performed in the morning, be-
tween 08:00 and 09:00 h; behavioural testing was
conducted between 10:00 and 15:00 h. No animal was ex-
cluded from statistical analysis.
Statistical analysis
Data and statistical analysis in this study comply with the rec-
ommendations on experimental design and analysis in phar-
macology (Curtis et al., 2015). Statistical analyses were
performed on raw data using Prism 5 Graphpad software
(GraphPad Software Inc., San Diego, CA, USA).
In vitro data are presented as mean ± SD.
In vivo data are presented as mean ± SEM. In the orofacial
test, data are presented as cumulative contact time (s). In CCI
experiments, DPA data are presented as paw withdrawal
threshold (g); cold allodynia data are presented as number
of paw withdrawals. The signiﬁcance of differences between
groups was determined by two-way repeated measurements
ANOVA followed by post hoc Bonferroni’s test. For the body
temperatures, the data are expressed as differences between
temperature obtained after injection (Tpost dose) and tempera-
ture before treatment (Tbasal); results are presented as
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ΔTb ± SEM. The signiﬁcance of differences between groups
was determined by one-way or two-way repeated measure-
ments ANOVA followed by post hoc Bonferroni’s test.
In icilin test, data are presented as number of WDS; the
signiﬁcance of differences between groups was determined
by Student’s t-test.
P < 0.05 was considered statistically signiﬁcant for all
tests.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.
org, the common portal for data from the IUPHAR/BPS Guide
to PHARMACOLOGY (Harding et al., 2018), and are perma-
nently archived in the Concise Guide to PHARMACOLOGY
2017/2018 (Alexander et al., 2017a,b,c).
Results
In vitro compounds characterization
DFL23448 was tested in an in vitro hTRPM8 calcium inﬂux as-
say using recombinant HEK-293 cell line. DFL23448 resulted
a potent TRPM8 blocker on icilin and Cooling Agent 10
(menthol analogue)-induced TRPM8 activation showing an
IC50 ± SD of 75 ± 9 and 55 ± 6 nM respectively (Figure 1A). Fol-
lowing our screening grid, the compound was also tested in
the Cold Stimulation Test in which the intracellular calcium
concentration was measured by detecting the ﬂuorescence
changes in response to the temperature change from 25 to
14°C, showing an IC50 ± SD of 21.4 ± 5 nM (Figure 1B).
Despite the high potency and selectivity, the oral use of
DFL23448 was limited by poor exposure in rats attributable
to its elimination through glucuronidation mechanisms.
With the aim to improve the metabolic stability of
DFL23448, Structure–Activity Relationship (SAR) studies
were performed starting from the knowledge of the
pharmacophore features of the ﬁrst series of TRPM8 blockers
from which DFL23448 derived.
A novel class of small MW of TRPM8 blockers has been
identiﬁed, and among the active compounds, DFL23693
was selected as the best molecule. DFL23693 is a moderately
less potent inhibitor comparing with its cognate DFL23448,
when evaluated through icilin and Cooling Agent 10-
induced TRPM8 activation, with an IC50 ± SD of 64 ± 6 and
81 ± 4 nM respectively (Figure 2A). On the other hand,
DFL23693 showed the same high potency of DF23448 in
thecoldphysiologicalactivationassay (IC50±SD=22.7±6nM;
Figure 2B).
DFL23693 andDFL23448 physicochemical and in vitro ab-
sorption, distribution, metabolism and excretion (ADME)
properties were obtained to provide the means for a full com-
parison of the compounds (Table 1). The compounds have the
pKa values close to that of the carboxylic acid (5.89 ± 0.02 for
DFL23448 and 4.34 ± 0.01 for DFL23693); this explains the
high protein binding in rat plasma that is 97.68 ± 0.01% for
DFL23448 and 98.99 ± 0.06% for DFL23693. Both com-
pounds have an excellent chemical stability (>98.5%) when
heated at 37°C for 5 days. The aqueous solubility of
DFL23448 and DFL23693 at pH 7.4 buffered solution was
0.631 ± 0.02 and 15.2 ± 0.11 mM respectively (Table 1).
Further characterization of the compounds showed the
absence of inhibition of hERG potassium channel. The
concentration–response curve of the test items on IKr ion
channel current resulted in an IC50 value of 410 ± 5 μM for
DFL23448 and 20 ± 0.9 μM for DFL23693 (Table 1). The com-
pounds also demonstrated no inhibition of selected CYP en-
zymes implicated in drug–drug interactions with an IC50
value >30 μM (Table 1).
Figure 1
Dose-response curves for effect of DFL23448 on responses induced by icilin (green line) and cooling agent 10 (red line) (A) and in the cold stim-
ulation test (B).
A new class of TRPM8 blockers in pain management
British Journal of Pharmacology (2018) •• ••–•• 7
In vitro selectivity of DFL23448 and
DFL23693 versus other TRP channels or
GPCRs
DFL23448 and DFL23693 showed a very good selectivity to-
wards a panel of GPCRs when tested at 10 μM in the
radioligand binding assay. DFL23448 and DFL23693 exhib-
ited an inhibition lower than 25% compared with the
radiolabelled reference compound speciﬁc on these targets:
α1A, α2A, β1 and β2 adrenoceptors; H1, H2, M2, M3, NK1, δ, κ,
μ, NOP (ORL1), 5-HT1A, CB2, D2, D3 and B1 receptors. In addi-
tion, DFL23448 and DFL23693 did not inhibit the calcium ef-
ﬂux in TRPV1, TRPV4, TRPA1 and Nav1.7 ion channels
triggered by capsaicin, GSK1016790A, isothiocyanate (AITC)
and veratridine respectively. The recorded IC50s were
>10 μM for all the ion channels tested (Table 2).
Figure 2
Dose-response curves for effect of DFL23693 on responses induced by icilin (green line) and cooling agent 10 (red line) (A) and in the cold stim-
ulation test (B).
Table 1
Physicochemical and in vitro ADME properties of DFL23448 and
DFL23693
Assay DFL23448 DFL23693
Aqueous solubility
at pH 7.4 (mM)
0.631 ± 0.02 15.2 ± 0.11
% chemical stability
(PBS, 37°C, 5 days)
98.9 ± 4.2 98.7 ± 5.1
pKa 5.89 ± 0.02 4.34 ± 0.01
Rat plasma protein
binding (%)
97.68 ± 0.01 98.99 ± 0.06
hERG inhibition
IC50 (μM)
410 ± 5 20 ± 0.9
CYP P450 inhibition
IC50 (μM)
>30 for all
tested isoforms
>30 for all
tested isoforms
Data are reported as mean ± SD.
Table 2
In vitro selectivity of DFL23448 and DFL23693 versus other TRP
channels or GPCRs
Receptor
% inhibition of control speciﬁc binding
[10 μM] (n = 3)
DFL23448 DFL23693
α1A 12.50 ± 4.58 13.90 ± 4.11
α2A 2.58 ± 3.84 1.41 ± 2.12
β1 4.66 ± 1.46 9.42 ± 1.32
β2 7.98 ± 0.99 5.15 ± 2.22
H1 10.82 ± 2.01 7.42 ± 0.91
H2 5.82 ± 2.52 0.41 ± 0.21
M2 17.65 ± 3.45 3.24 ± 1.25
M3 11.67 ± 2.42 15.76 ± 1.03
NK1 2.02 ± 0.81 3.12 ± 0.91
μ 21.85 ± 3.23 3.61 ± 1.27
κ 21.57 ± 6.53 17.62 ± 4.18
δ 1.86 ± 1.50 2.96 ± 0.17
NOP 14.47 ± 4.55 11.3 ± 3.93
5-HT1A 4.05 ± 1.71 5.9 ± 1.81
CB2 10.58 ± 3.56 12.34 ± 4.09
D2 7.57 ± 1.68 8.90 ± 3.23
D3 2.51 ± 1.09 11.34 ± 3.98
B1 21.54 ± 4.51 4.67 ± 2.65
IC50 towards ion channels
TRPV1 IC50 > 10 μM IC50 > 10 μM
TRPV4 IC50 > 10 μM IC50 > 10 μM
TRPA1 IC50 > 10 μM IC50 > 10 μM
Nav1.7 IC50 > 10 μM IC50 > 10 μM
C De Caro et al.
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Pharmacokinetics in the rats
The pharmacokinetic parameters of DFL23448 and
DFL23693 following single i.v. and p.o. administration to
male rats were evaluated (Table 3). I.v. administration of
DFL23448 (3 mg·kg1) showed a clearance of 3.11 ± 0.11-
mL·min1·kg1and a t1/2 of 0.74 ± 0.05 h. The distribution
volume was 0.082 ± 0.012 L·kg1 P.o. administration of 10-
mg·kg1 of DFL23448 caused a maximum plasma concentra-
tion (Cmax) of 47 ± 6 ng·mL1 and the tmax occurred at
4.51 ± 0.32 h after dosing. The p.o. t1/2 was 5.11 ± 0.43 h. In-
travenous administration of DFL23693 at 5 mg·kg1 showed
a low clearance (5.31 ± 0.31 mL·min1·kg1) with a t1/2 of
3.15 ± 0.10 h and a distribution volume of 1.69 ± 0.11 L·kg1.
Urine analysis data showed that a very small quantity of
DFL23693 (1.51 ± 0.08%) was excreted through urine over a
period of 72 h. P.o. administration at 10 mg·kg1 of
DFL23693 showed a Cmax of 10 673 ± 805 ng·mL1 and the
tmax occurred at 15 min after dosing. The p.o. t1/2 was
3.13 ± 0.32 h. DFL23693 showed a high p.o. absolute bio-
availability (F%) of 98.8%. Table 3 summarizes the pharma-
cokinetic parameters of the compounds.
In vivo results
Effect of DFL23693 and DFL23448 in formalin-induced orofacial
pain hypersensitivity. The formalin test is an important
means of assessing pain-evoked behaviours induced by
moderately intense and long-lasting noxious stimuli. As
recently reported (Cervantes-Durán et al., 2016), intraplantar
injection of formalin produces a long-lasting secondary
allodynia and hyperalgesia in rats. In agreement with these
results, we observed that upper lip formalin injection in
vehicle treated-group produced a signiﬁcant reduction of
contact time 24 h after challenge both in mechanical
(Figure 3A, B) and cold (Figure 3C, D) stimulation test (white
bars; #P < 0.05 vs. the respective basal group). Oral
pretreatment with DFL23693 (10 mg·kg1; administrated 3 h
before orofacial test, in agreement with its pharmacokinetic
characteristics) signiﬁcantly decreased formalin-induced
pain hypersensibility; indeed, 24 h following formalin
challenge, the compound increased the contact time in
both mechanical and cold allodynia tests (Figure 3A, C,
grey-white columns; *P < 0.05 vs. vehicle + 24 h group). A
very similar activity was also obtained with i.v. DFL23448
treatment (10 mg·kg1); on the basis of its pharmacokinetic
proﬁle, the administration of the drug 1 h before orofacial
test produced a signiﬁcant antinociceptive effect on both
mechanical and cold stimuli (Figure 3B, D, respectively;
grey-black columns; *P < 0.05 vs. vehicle + 24 h group).
Effect of DFL23693 and DFL23448 in CCI-induced cold and
mechanical allodynia. CCI model is one of the most
commonly employed animal model of neuropathic pain. In
this model, we evaluated the efﬁcacy of the compounds 7
and 14 days after sciatic nerve ligation, time in which
allodynia and hyperalgesia are well evident (Bennett and
Xie, 1988; Xing et al., 2007). As illustrated in Figures 4 and
5, CCI-vehicle treated animals showed a signiﬁcant cold and
mechanical allodynia if compared with sham rats. In
particular, in cold allodynia experiments, the number of
paw withdrawal threshold on ipsilateral paw of vehicle T
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treated groups resulted signiﬁcantly increased 7 and 14 days
after surgery, due to neuropathy (Figure 4A, B, white bars;
#P < 0.05 vs. sham rats); no effect was observed on the
contralateral (unligated) paws (data not shown). Oral
DFL23693 administration (10 mg·kg1) signiﬁcantly
reduced the number of ipsilateral paw withdrawal at 3 and
5 h post dose (Figure 4A, grey-white columns, *P < 0.05 vs.
CCI-vehicle treated rats and Figure 4B, grey-white columns,
*P < 0.05 vs. CCI-vehicle treated rats); no effect was
observed at 1 h. Intravenous DFL23448 administration
(10 mg·kg1) showed a signiﬁcant reduction of cold
allodynia only 1 h post dose on days 7 and 14 following CCI
(Figure 4A, B, grey-black columns, *P < 0.05 vs. CCI-vehicle
rats), whereas no activity was determinate 3 and 5 h post dose
(Figure 4A, B, grey-black columns). In DPA test, paw
withdrawal threshold on ipsilateral paw resulted
signiﬁcantly reduced at days 7 and 14, due to neuropathy
(Figure 5A, B, white columns; #P < 0.05 vs. sham rats); no
effect was observed on the contralateral (unligated) paws
(data not shown). At 7 and 14 days from sciatic nerve
ligation, DFL23693 (10 mg·kg1 p.o.) showed a signiﬁcant
reduction of mechanical allodynia at 3 and 5 h post
treatment (Figure 5A, B, grey-white columns; *P < 0.05 vs.
CCI-vehicle treated rats). In agreement with the results
obtained in cold allodynia, DFL23448 (10 mg·kg1 i.v.)
signiﬁcantly increased paw withdrawal latency only 1 h
post dose (Figure 5A, B, grey-black columns; *P < 0.05 vs.
CCI-vehicle treated rats), whereas no activity was observed
at 3 and 5 h (Figure 5A, B, grey-black columns).
Effect of DFL23693 and DFL23448 on body temperature. We
evaluated the effects of the compounds on Tb. During the
ﬁrst day of treatment, DFL23693 (10 mg·kg1 p.o.) produced
a signiﬁcant decrease of Tb by 1.91°C at 3 h and 1.4°C at 5 h
(Figure 6A, black square; *P < 0.05 vs. vehicle group), while no
signiﬁcant effect was detectable at 1 and 7 h following p.o.
administration. I.v. administration of DFL23448 (10 mg·kg1)
produced a signiﬁcant effect with a Tb decrease of 0.8°C at
0.5 h and 1.08°C at 1 h (*P < 0.05 vs. vehicle group), while no
effect was detectable at 2 and 3 h (Figure 6B, black square). As
expected, intramuscular administration of icilin (7.5 mg·kg1)
increased Tb values with a maximum of 1.1°C 2 h after
treatment (Figure 6B, black triangle; *P < 0.05 vs. vehicle
Figure 3
Effect of vehicle, DFL23693 and DFL23448 on formalin-induced mechanical (A and B) and thermal (C and D) allodynia. After 24 h from formalin,
rats were treated with vehicle, DFL23693 (10 mg·kg1 p.o.) and DFL23448 (10 mg·kg1 i.v.); the test was done 3 h following p.o. administration
(DFL23693) or 1 h following i.v. administration (DFL23448). The cumulative contact time was counted for 10min. Data are shown asmean ± SEM
of 10 animals per group. #P < 0.05 versus the respective basal response; *P < 0.05 versus vehicle + 24 h group.
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group). Icilin was used as negative control, and it was
administered only on the ﬁrst day of treatment.
A marked reduction of magnitude in Tb decrease starting
from day 2 was visible for both the compounds at each of
the considered experimental time. In particular, DFL23693
3 h post dose induced a decrease of 0.96°C on day 2, 0.63°C
on day 3 and 0.27°C on day 4 respectively (Figure 6C).
DFL23448 1 h post dose induced a decrease of 0.53, 0.34
and 0.38°C on days 2, 3 and 4 respectively (Figure 6D).
Effect of DFL23693 and DFL23448 on icilin-induced WDS. To
evaluate the compounds’ ability to block the spontaneous
wet-dog shake induced by icilin, we administered DFL23693
or DFL23448 before the challenge with icilin (1 mg·kg1
i.p.) and recorded WDS for a period of 30 min. In the
vehicle treated group, a mean of about 170 shakes was
counted during the 30 min interval (Figure 7, white
column). Pretreatment with DFL23693 (10 mg·kg1 p.o.)
and DFL23448 (10 mg·kg1 i.v.) signiﬁcantly reduced icilin-
induced WDS. In particular, in p.o. DFL23693-pretreated
(3 h) animals, about 77 shakes were counted, demonstrating
a reduction of 51% (Figure 7A, grey-white column;
*P < 0.05). In i.v. DFL23448-pretreated (1 h) rats, about 109
shakes were counted throughout the 30 min observation
Figure 5
Effect of vehicle, DFL23693 and DFL23448 on CCI-induced mechanical allodynia 7 and 14 days after injury. On day 7 following sciatic nerve li-
gation, rats were treated with vehicle, p.o. DFL23693 (10 mg·kg1 p.o.) and i.v. DFL23448 (10 mg·kg1 i.v.). Allodynia induced by mechanical
stimulus was evaluated 1, 3 and 5 h post dose on ipsilateral paw. Data are shown as mean ± SEM of 10 animals per group. #P< 0.05 versus Sham;
*P < 0.05 versus vehicle group.
Figure 4
Effect of vehicle, DFL23693 and DFL23448 on CCI-induced cold allodynia 7 and 14 days after injury. On day 7 following sciatic nerve ligation, rats
were treated with vehicle, p.o. DFL23693 (10 mg·kg1 p.o.) and i.v. DFL23448 (10 mg·kg1 i.v.). Allodynia induced by cold stimulus was evalu-
ated 1, 3 and 5 h post dose on ipsilateral paw. Data are shown as mean ± SEM of 10 animals per group. #P < 0.05 versus Sham; *P < 0.05 versus
vehicle group.
A new class of TRPM8 blockers in pain management
British Journal of Pharmacology (2018) •• ••–•• 11
period with a reduction of 37% (Figure 7B, grey-black
column; *P < 0.05).
Discussion
In nearly two decades of research, numerous TRP channels,
including TRPA1, TRPV1 and TRPV4, have been clearly dem-
onstrated to be keymediators of pain process andmodulation
of these channels that have been proven effective in many
preclinical models of pain and in some cases useful treat-
ments for human diseases.
Among the pain-related TRPs, TRPM8 has been progres-
sively recognized for its role in the modulation of pain and
nociception (Fernández-Peña and Viana, 2013). In recent
years, several manuscripts documented an increase of
TRPM8 expression in different pain models including
chemotherapy-induced neuropathy (Gauchan et al., 2009),
experimental colitis (Hosoya et al., 2014) and diabetic neu-
ropathy (Nam et al., 2014), conﬁrming its role in injury-
evoked allodynia in the somatic sensory nervous system
(Harrington et al., 2011; Sarria et al., 2012) and underlining
the key role of this channel in pain management (Dai,
2016). Notably, in animal models of neuropathic pain, the
expression of TRPM8 increases in DRGs in response to sciatic
or spinal nerve damage, and this increase correlates closely
with the development of neuropathic pain (Frederick et al.,
2007; Su et al., 2011; Koh et al., 2016). Blocking the activity
of the channel by the administration of TRPM8 antagonists
or by genetic ablation using mice lacking TRPM8, signiﬁ-
cantly attenuated thermal responses in nerve injury-induced
pain (Knowlton et al., 2011; Patel et al., 2014). This evidence
suggests that the in vivo antagonism of TRPM8 holds promise
for the successful treatment of neuropathic cold hypersensi-
tivity (Marwaha et al., 2016; Weyer and Letho, 2017). A key
challenge in the discovery of TRPM8 blockers is the identiﬁ-
cation of highly selective molecules with a good pharmaco-
kinetic proﬁle suitable to provide an efﬁcacious dose
response. In this paper, we describe two novel small MW
TRPM8 inhibitors that exhibited a clear efﬁcacy in the reduc-
tion of cold and mechanical allodynia in acute and chronic
pain models. In vitro data showed that both DFL23693 and
DFL23448 potently inhibit human TRPM8 activation by
chemical and physiological stimulation and display a high
selectivity. In vivo, the compounds were assessed for their
TRPM8 antagonist activity under both normal and patholog-
ical conditions. In the in vivo experiments, DFL23693 was
given by p.o. administration since it showed complete p.o.
bioavailability (98.8%) in rats, whereas compound
DFL23448 was administered i.v. due to its poor oral bioavail-
ability (0.99%).
In icilin-induced WDS, a model of skeletal muscle-
mediated heat generation in which the role of TRPM8 has
been widely characterized (Werkheiser et al., 2006; Rossi
Figure 6
Effect of vehicle, DFL23693 (A), DFL23448 (B) and icilin (B) on body temperature. Rats were treated with vehicle, DFL23693 (10 mg·kg1 p.o.)
and DFL23448 (10 mg·kg1 i.v.) for four consecutive days; each day Tb was measured 1–3 to 5–7 h post DFL23693 dose and 0.5–1 to 2–3 h post
DFL23448 dose. Icilin (7.5 mg·kg1 i.m.) was used as negative control, and it was administered only on the ﬁrst day of treatment. Tb data collected
n the ﬁrst day of treatment (A and B) and at 3 h post dose for DFL23693 (C) and 1 h post dose for DFL23448 (D), for 4 days of treatment. Data are
shown as mean [differences between temperature obtained after injection (Tpost dose) and temperature before treatment (Tbasal)] ± SEM of 10 an-
imals per group. *P < 0.05 versus vehicle group.
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et al., 2009), systemic administration of the drugs was able to
reduce the numbers of WDS produced by icilin, in line with
previous literature (Tamayo et al., 2012; Lehto et al., 2015).
Gavva et al. (2012) showed that the administration of selec-
tive TRPM8 antagonists produces a small but signiﬁcant de-
crease in Tb, impossible to be reproduced in TRPM8
knockout mice, suggesting that the body temperature de-
crease is entirely mediated by TRPM8. In agreement with
these ﬁndings and other published data (Ito et al., 2016),
our results show that a single administration of DFL23693
or DFL23448 resulted in transient hypothermia that ap-
peared attenuated after repeated dosing of the compounds.
It has been widely demonstrated that TRPM8 is involved in
thermoregulation (Gavva et al., 2012), a role that is not en-
tirely unexpected given that other temperature sensitive ion
channels, particularly the heat-gated TRPV1, have also been
implicated in the regulation of body temperature (Gavva
et al., 2007; Gavva et al., 2008). The precise role of TRPM8 in
thermoregulation and energetic homeostasis is still unclear.
In fact, although only a modest defect in thermoregulation
under speciﬁc environmental conditions has been observed
in TRPM8 null mice, TRPM8 activation on the skin has been
proposed to act as a thermostat to prevent further cooling
(Tajino et al., 2011), and subcutaneous injection of icilin
results in a clear hyperthermic effect that is absent in
TRPM8 knockout mice (Knowlton et al., 2010). In contrast
with the above preclinical results, in the ﬁrst clinical trial
conducted in healthy volunteers using a TRPM8 antagonist,
PF-05105679, the compound showed a clear pharmacological
activity on cold pain in the absence of hypothermia at any
dose tested (Winchester et al., 2014), paving the way to fur-
ther clinical investigation on this class of molecules. Several
new TRPM8 antagonists have been reported to be effective
in vitro in the nanomolar range and investigated for their ther-
apeutic potential in the treatment of cold hypersensitivity in
different neuropathic pain models and in the management of
urological disorders (Patel et al., 2014; Lehto et al., 2015;
Mistretta et al., 2016). To conﬁrm the involvement of this
channel in pain, it has been demonstrated that TRPM8 is nec-
essary for the detection of chemical and thermal cooling
stimuli in some sensory neurons and that TRPM8 knockout
CCI-mice did not exhibit signiﬁcant increase in acetone-
induced cold allodynia (Colburn et al., 2007). In coherence
with this observation, Xing et al. (2007) showed that
TRPM8-immunoreactive positive neurons in the L5 DRGs
was increased in CCI animal model and that a non-selective
TRPM8 blocker attenuated cold allodynic responses in these
mice. In a recent paper, Su et al. (2011) showed that intrathe-
cal administration of menthol induced cold sensation and
that the injection of a TRPM8 antisense oligonucleotide at-
tenuated cold hyperalgesia in CCI rats. Our data showed that
in cold allodynia experiments, systemic administration of
DFL23693 and DFL23448 reduced the number of paw with-
drawal threshold produced by acetone, and surprisingly, the
Figure 7
Effect of vehicle, DFL23693 (A) and DFL23448 (B) on icilin-induced WDS. Rats were pretreated with vehicle, DFL23693 (10 mg·kg1 p.o.) and
DFL23448 (10 mg·kg1 i.v.). The test was done 3 h following p.o. administration and 1 h following i.v. administration. The number of WDS were
counted for 30 min following icilin injection (1 mg·kg1 i.p.). Data are shown as mean ± SEM of 10 animals per group. *P < 0.05 versus vehicle
group.
A new class of TRPM8 blockers in pain management
British Journal of Pharmacology (2018) •• ••–•• 13
antiallodynic effect was also observed in response to mechan-
ical stimulation, thus suggesting an involvement of TRPM8
also in mechanical allodynia. Our data are also in agreement
with recent ﬁndings by Sałat and Filipek (2015), which
showed the effect of a speciﬁc TRPM8 antagonist, AMTB, on
mechanical allodynia in amousemodel of paclitaxel-induced
neuropathic pain. These results are also supported by ﬁnd-
ings demonstrating that neuropathic pain models, including
CCI, present spontaneous discharge in myelinated and un-
myelinated ﬁbres (Zimmermann, 2001; Seal et al., 2009), a
hallmark that strongly contributes to the development and
maintenance of neuropathic pain, and that TRPM8 is
expressed on both ﬁbres (Wasner et al., 2004; Dhaka et al.,
2008). The higher efﬁcacy in the in vivo models of
DFL23693 compared with DFL23448 is coherent with the im-
proved PK-ADME properties of the compound. Indeed, the
rapid onset and short duration of the pharmacological effect
of DFL23448 perfectly reﬂect its pK proﬁle (tmax and t1/2).
Oral administration of DFL23693 results in plasma concen-
trations higher than in vitro IC50 both at 3 and 5 h post treat-
ment (97 and 63 nM, respectively) thus explaining the
sustained efﬁcacy in cold and mechanical allodynia models.
Furthermore, the low volume of distribution (0.082 ± 0.012-
L·kg1) of DFL23448, associated with its high protein bind-
ing accounts for a limited distribution to peripheral
terminals of sensory neurons that strongly impacts on its
in vivo efﬁcacy. It is worth mentioning that also the activation
of TRPM8 has been associated with an analgesic effect and
that TRPM8 agonists such as menthol or icilin can alleviate
pain in neuropathic animals models (Proudfoot et al., 2006).
This goes with the well-known fact that cooling the skin
produces a soothing sensation on the background of inﬂam-
matory pain. The nervous circuitries involved in these anal-
gesic effects of cold temperature are currently unclear, and
in this complex scenario, translating novel potent and selec-
tive TRPM8 modulators into the clinic will allow a better
comprehension of the therapeutic potential and safety
proﬁle of these agents for pain management. While the role
of TRPM8 in chronic pain (such as chronic inﬂammation or
neuropathic pain) has been thoroughly described, there is
little information on its contribution in acute pain.
Capsaicin- or formalin-induced neurogenic inﬂammation
are two classical acute pain models abundantly used to eval-
uate the antinociceptive properties of drugs; even if behav-
ioural symptoms (oedema licking or biting responses) are
similar regardless of the kind of chemical used, they have
distinct mechanisms of action. Indeed, capsaicin is an ago-
nist of TRPV1 channels, whereas formalin not only stimu-
lates TRPA1 channels (McNamara et al., 2007), but it has
also others pronociceptive mechanisms (Coste et al., 2012;
Sasso et al., 2012). Precisely for its characteristic to develop
a more articulated pain, we used formalin-induced orofacial
pain. Following formalin injection, rats displayed orofacial
rubbing and rapid head ﬂinching due to direct activation
of primary afferent neurons (phase I); then a persistent pain
induction (phase II) was associated with the central
sensitization and release of multiple inﬂammatory factors
(Luccarini et al., 2006). As recently reported by García
et al. (2014), ionic channels participate in the acute
nociception induced by formalin as well as in the develop-
ment and maintenance of secondary mechanical allodynia
and hyperalgesia. Speciﬁcally, several published data have
highlighted a role for the thermo-channel TRPA1 in
formalin-induced pain as well as in other different patho-
logical pain conditions including neuropathic pain models
(del Camino et al., 2010; Wei et al., 2011). Here, we hypoth-
esized that TRPM8 could play a key regulatory role in the
development of symptoms closely correlated to hypersensi-
tivity. TRPM8 channels are expressed in many trigeminal
neurons (McKemy et al., 2002) and trigeminal nerve end-
ings (Takashima et al., 2007), but their speciﬁc involvement
in trigeminal pain is still unknown. The novel selective
TRPM8 inhibitors that have been fully characterized in this
study are able to reduce orofacial allodynia induced by for-
malin at 24 h. Indeed, both compounds, DFL23693 and
DFL23448, increased signiﬁcantly the contact time to both
mechanical and cold stimuli suggesting a key role of this
channel in formalin-induced long-lasting mechanical and
termal allodynia in rats. These ﬁndings demonstrate for
the ﬁrst time that TRPM8 blockers are able to reduce pain
hypersensitivity induced by formalin in the orofacial test re-
inforcing the hypothesis that TRPM8 antagonists may have
a role in the therapeutic treatment of orofacial pain
conditions.
In conclusion, in this paper, the authors, having identi-
ﬁed a novel class of selective TRPM8 antagonists with unique
binding properties to the ion channel, report their full in vitro
and in vivo characterization and the evaluation of their effect
on cold and mechanical allodynia in relevant inﬂammatory
and neuropathic pain models. Overall, these ﬁndings encour-
age the use of TRPM8 modulators in the therapeutic manage-
ment of cold and tactile-evoked pain, preferably in the
orofacial region.
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